Published in Nucleic Acids Res on July 22, 2004
Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci U S A (2007) 5.50
Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci U S A (2007) 3.30
Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci U S A (2005) 3.24
Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest (2007) 2.78
Progress in microRNA delivery. J Control Release (2013) 1.58
Nonviral methods for siRNA delivery. Mol Pharm (2009) 1.50
Matrices and scaffolds for DNA delivery in tissue engineering. Adv Drug Deliv Rev (2007) 1.47
Cellular delivery of small interfering RNA by a non-covalently attached cell-penetrating peptide: quantitative analysis of uptake and biological effect. Nucleic Acids Res (2006) 1.36
Engineering RNA for targeted siRNA delivery and medical application. Adv Drug Deliv Rev (2010) 1.32
Micro-RNA-31 controls hair cycle-associated changes in gene expression programs of the skin and hair follicle. FASEB J (2010) 1.21
Delivery systems for the direct application of siRNAs to induce RNA interference (RNAi) in vivo. J Biomed Biotechnol (2006) 1.21
Differentially charged hollow core/shell lipid-polymer-lipid hybrid nanoparticles for small interfering RNA delivery. Angew Chem Int Ed Engl (2011) 1.13
Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev (2013) 1.12
Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. Br J Cancer (2009) 1.08
Efficient in vitro siRNA delivery and intramuscular gene silencing using PEG-modified PAMAM dendrimers. Mol Pharm (2012) 1.06
Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies. Am J Pathol (2007) 1.01
Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev (2015) 1.01
GEP100-Arf6-AMAP1-cortactin pathway frequently used in cancer invasion is activated by VEGFR2 to promote angiogenesis. PLoS One (2011) 1.00
Concepts in in vivo siRNA delivery for cancer therapy. J Cell Physiol (2009) 0.98
Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections. Theranostics (2014) 0.96
Targeted induction of interferon-λ in humanized chimeric mouse liver abrogates hepatotropic virus infection. PLoS One (2013) 0.95
microRNA therapies in cancer. Mol Cell Ther (2014) 0.95
Therapeutic regulation of gene expression in the inner ear using RNA interference. Adv Otorhinolaryngol (2009) 0.94
Y-box binding protein-1 regulates cell proliferation and is associated with clinical outcomes of osteosarcoma. Br J Cancer (2013) 0.94
Atelocollagen-mediated systemic delivery prevents immunostimulatory adverse effects of siRNA in mammals. Mol Ther (2011) 0.92
MicroRNAs in cancer diagnosis and therapy: from bench to bedside. Surg Today (2012) 0.90
Rb inactivation accelerates neoplastic growth and substitutes for recurrent amplification of cIAP1, cIAP2 and Yap1 in sporadic mammary carcinoma associated with p53 deficiency. Oncogene (2010) 0.90
Recent In Vivo Evidences of Particle-Based Delivery of Small-Interfering RNA (siRNA) into Solid Tumors. J Pharm Innov (2014) 0.89
Gene silencing by RNAi in mouse Sertoli cells. Reprod Biol Endocrinol (2008) 0.88
Increased RNAi is related to intracellular release of siRNA via a covalently attached signal peptide. RNA (2009) 0.85
The living microarray: a high-throughput platform for measuring transcription dynamics in single cells. BMC Genomics (2011) 0.84
Anti-tumour effects of small interfering RNA targeting anion exchanger 1 in experimental gastric cancer. Br J Pharmacol (2012) 0.84
Efficient inhibition of tumor angiogenesis and growth by a synthetic peptide blocking S100A4-methionine aminopeptidase 2 interaction. Mol Ther Methods Clin Dev (2015) 0.84
Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotides. Ther Deliv (2011) 0.82
Targeted delivery of siRNA. J Biomed Biotechnol (2006) 0.81
Harnessing RNAi nanomedicine for precision therapy. Mol Cell Ther (2014) 0.81
RNA therapeutics targeting osteoclast-mediated excessive bone resorption. Adv Drug Deliv Rev (2011) 0.80
Cathepsin L inhibition prevents murine autoimmune diabetes via suppression of CD8(+) T cell activity. PLoS One (2010) 0.80
RNAi reduces expression and intracellular retention of mutant cartilage oligomeric matrix protein. PLoS One (2010) 0.79
RNAi and cancer: Implications and applications. J RNAi Gene Silencing (2006) 0.77
Establishment of a positive-readout reporter system for siRNAs. J RNAi Gene Silencing (2009) 0.77
New aspects of gene-silencing for the treatment of cardiovascular diseases. Pharmaceuticals (Basel) (2013) 0.77
Virus-Inspired Self-Assembly Nanofibers with Aggregation-Induced Emission for Highly Efficient and Visible Gene Delivery. ACS Appl Mater Interfaces (2017) 0.77
Effects of atelocollagen on neural stem cell function and its migrating capacity into brain in psychiatric disease model. J Neural Transm (Vienna) (2013) 0.76
SUMO-conjugating enzyme UBC9 promotes proliferation and migration of fibroblast-like synoviocytes in rheumatoid arthritis. Inflammation (2014) 0.76
Allele dependent silencing of collagen type I using small interfering RNAs targeting 3'UTR Indels - a novel therapeutic approach in osteogenesis imperfecta. Int J Med Sci (2013) 0.76
Therapeutic potential of targeting cell division cycle associated 5 for oral squamous cell carcinoma. Oncotarget (2016) 0.76
Photomechanical wave-driven delivery of siRNAs targeting intermediate filament proteins promotes functional recovery after spinal cord injury in rats. PLoS One (2012) 0.76
Gene-Activated Matrix Comprised of Atelocollagen and Plasmid DNA Encoding BMP4 or Runx2 Promotes Rat Cranial Bone Augmentation. Biores Open Access (2015) 0.75
Delivery systems for in vivo use of nucleic Acid drugs. Drug Target Insights (2007) 0.75
MiR-29a Assists in Preventing the Activation of Human Stellate Cells and Promotes Recovery From Liver Fibrosis in Mice. Mol Ther (2016) 0.75
Nanoparticle-based strategy for personalized B-cell lymphoma therapy. Int J Nanomedicine (2016) 0.75
Specific inhibition of tumor cells by oncogenic EGFR specific silencing by RNA interference. PLoS One (2013) 0.75
Fundamental study of detection of muscle hypertrophy-oriented gene doping by myostatin knock down using RNA interference. J Sports Sci Med (2012) 0.75
Regenerative medicine in orthopedics using cells, scaffold, and microRNA. J Orthop Sci (2014) 0.75
RNA interference-based nanosystems for inflammatory bowel disease therapy. Int J Nanomedicine (2016) 0.75
Silencing sexually transmitted infections: topical siRNA-based interventions for the prevention of HIV and HSV. Infect Dis Obstet Gynecol (2014) 0.75
An Atelocollagen Coating for Efficient Local Gene Silencing by Using Small Interfering RNA. Mol Ther Nucleic Acids (2017) 0.75
Effects of atelocollagen formulation containing oligonucleotide on endothelial permeability. J Drug Deliv (2012) 0.75
Glutathione-responsive nano-transporter-mediated siRNA delivery: silencing the mRNA expression of Ras. Protoplasma (2012) 0.75
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 72.56
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 57.23
A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet (2003) 12.16
Activation of the interferon system by short-interfering RNAs. Nat Cell Biol (2003) 8.63
Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol (2002) 8.31
RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med (2003) 7.37
U6 promoter-driven siRNAs with four uridine 3' overhangs efficiently suppress targeted gene expression in mammalian cells. Nat Biotechnol (2002) 6.66
Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet (2003) 6.49
Effective expression of small interfering RNA in human cells. Nat Biotechnol (2002) 6.02
An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet (2003) 5.82
siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol (2002) 5.65
Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol (2003) 3.27
Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. Neoplasia (2001) 2.97
A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res (2004) 2.72
Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. Nucleic Acids Res (2003) 2.34
Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun (2002) 1.75
Small interfering RNA and gene silencing in transgenic mice and rats. FEBS Lett (2002) 1.71
Use of lentiviral vectors for delivery of small interfering RNA. Cancer Biol Ther (2003) 1.67
New delivery system for plasmid DNA in vivo using atelocollagen as a carrier material: the Minipellet. Nat Med (1999) 1.62
Noninvasive imaging of spontaneous retinoblastoma pathway-dependent tumors in mice. Cancer Res (2002) 1.46
Screening for gene function in chicken embryo using RNAi and electroporation. Nat Biotechnol (2002) 1.42
Collagen as a biomaterial. Annu Rev Biophys Bioeng (1974) 1.40
Gene silencing mediated by small interfering RNAs in mammalian cells. Curr Med Chem (2003) 1.28
Use of adeno-associated viral vector for delivery of small interfering RNA. Oncogene (2003) 1.15
Atelocollagen-based gene transfer in cells allows high-throughput screening of gene functions. Biochem Biophys Res Commun (2001) 1.09
Biomaterials for gene delivery: atelocollagen-mediated controlled release of molecular medicines. Curr Gene Ther (2001) 1.08
Atelocollagen for protein and gene delivery. Adv Drug Deliv Rev (2003) 1.04
Potential of atelocollagen-mediated systemic antisense therapeutics for inflammatory disease. Hum Gene Ther (2004) 0.96
Expression of the HST1 oncogene in human germ cell tumors. Biochem Biophys Res Commun (1988) 0.93
Antisense oligodeoxynucleotide against HST-1/FGF-4 suppresses tumorigenicity of an orthotopic model for human germ cell tumor in nude mice. J Gene Med (2003) 0.90
Effective prevention of thrombocytopenia in mice using adenovirus-mediated transfer of HST-1 (FGF-4) gene. J Clin Invest (1995) 0.82
Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem (2010) 8.09
Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci (2010) 5.17
An acidic matrix protein, Pif, is a key macromolecule for nacre formation. Science (2009) 3.38
Residual embryonic cells as precursors of a Barrett's-like metaplasia. Cell (2011) 3.36
Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci U S A (2005) 3.24
Distal airway stem cells yield alveoli in vitro and during lung regeneration following H1N1 influenza infection. Cell (2011) 3.00
Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther (2009) 2.92
microRNA as a new immune-regulatory agent in breast milk. Silence (2010) 2.20
Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol Ther (2012) 2.15
Adipose tissue-derived mesenchymal stem cells as a source of human hepatocytes. Hepatology (2007) 2.14
Sentinel node mapping guided by indocyanine green fluorescence imaging in gastric cancer. Ann Surg (2009) 2.04
Hair transplantation for reconstruction of scalp defects using artificial dermis. Dermatol Surg (2011) 2.01
Bone-marrow-derived myofibroblasts contribute to the cancer-induced stromal reaction. Biochem Biophys Res Commun (2003) 2.00
The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PLoS One (2011) 1.81
miR-22 represses cancer progression by inducing cellular senescence. J Cell Biol (2011) 1.78
MicroRNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease-13 expression. Mol Ther (2011) 1.77
IFATS collection: in vivo therapeutic potential of human adipose tissue mesenchymal stem cells after transplantation into mice with liver injury. Stem Cells (2008) 1.75
Intensive cardiac management in patients with trisomy 13 or trisomy 18. Am J Med Genet A (2008) 1.74
Rapid hepatic fate specification of adipose-derived stem cells and their therapeutic potential for liver failure. J Gastroenterol Hepatol (2008) 1.68
A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc Natl Acad Sci U S A (2012) 1.64
Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. Cancer Res (2002) 1.64
Secretory microRNAs as a versatile communication tool. Commun Integr Biol (2010) 1.64
Identification of NAP1, a regulatory subunit of IkappaB kinase-related kinases that potentiates NF-kappaB signaling. Mol Cell Biol (2003) 1.63
Neutral sphingomyelinase 2 (nSMase2)-dependent exosomal transfer of angiogenic microRNAs regulate cancer cell metastasis. J Biol Chem (2013) 1.62
Inhibition of Stabilin-2 elevates circulating hyaluronic acid levels and prevents tumor metastasis. Proc Natl Acad Sci U S A (2012) 1.61
Hedgehog signal activation in gastric pit cell and in diffuse-type gastric cancer. Gastroenterology (2006) 1.60
Generation of genetically modified rats from embryonic stem cells. Proc Natl Acad Sci U S A (2010) 1.59
Dicer is required for maintaining adult pancreas. PLoS One (2009) 1.59
One Argonaute family member, Eif2c2 (Ago2), is essential for development and appears not to be involved in DNA methylation. Genomics (2007) 1.56
MOZ is essential for maintenance of hematopoietic stem cells. Genes Dev (2006) 1.56
Therapeutic potential of RNA interference against cancer. Cancer Sci (2006) 1.49
Competitive interactions of cancer cells and normal cells via secretory microRNAs. J Biol Chem (2011) 1.48
Combined functional genome survey of therapeutic targets for hepatocellular carcinoma. Clin Cancer Res (2010) 1.47
Prognosis of patients undergoing hepatectomy for solitary hepatocellular carcinoma originating in the caudate lobe. Surgery (2011) 1.44
Stacking of conical molecules with a fullerene apex into polar columns in crystals and liquid crystals. Nature (2002) 1.42
Association between dementia and midlife risk factors: the Radiation Effects Research Foundation Adult Health Study. J Am Geriatr Soc (2003) 1.41
The therapeutic potential of mesenchymal stem cell-derived extracellular vesicles. Proteomics (2013) 1.39
RPN2 gene confers docetaxel resistance in breast cancer. Nat Med (2008) 1.38
Metal-intercalated aromatic hydrocarbons: a new class of carbon-based superconductors. Phys Chem Chem Phys (2011) 1.37
LGR5-positive colon cancer stem cells interconvert with drug-resistant LGR5-negative cells and are capable of tumor reconstitution. Stem Cells (2012) 1.36
MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. Biomarkers (2009) 1.35
Imaging exosome transfer from breast cancer cells to stroma at metastatic sites in orthotopic nude-mouse models. Adv Drug Deliv Rev (2012) 1.34
In vivo analysis of insertional torque during pedicle screwing using cortical bone trajectory technique. Spine (Phila Pa 1976) (2014) 1.33
A faithful method for PCR-mediated global mRNA amplification and its integration into microarray analysis on laser-captured cells. Biochem Biophys Res Commun (2003) 1.33
Negative regulation of platelet clearance and of the macrophage phagocytic response by the transmembrane glycoprotein SHPS-1. J Biol Chem (2002) 1.30
Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes. Sci Rep (2013) 1.28
Low heart rate variability is a risk factor for sudden cardiac death in type 2 diabetes. Diabetes Res Clin Pract (2004) 1.28
Comprehensive miRNA expression analysis in peripheral blood can diagnose liver disease. PLoS One (2012) 1.28
MiR-150 is associated with poor prognosis in esophageal squamous cell carcinoma via targeting the EMT inducer ZEB1. Cancer Sci (2012) 1.27
Trash or Treasure: extracellular microRNAs and cell-to-cell communication. Front Genet (2013) 1.25
Differentiation of embryonic stem cells into hepatocytes: biological functions and therapeutic application. Hepatology (2003) 1.24
An adult case of Bochdalek hernia complicated with hemothorax. Respiration (2004) 1.23
Image fusion between 18FDG-PET and MRI/CT for radiotherapy planning of oropharyngeal and nasopharyngeal carcinomas. Int J Radiat Oncol Biol Phys (2002) 1.23
Evolutional study on acetylcholine expression. Life Sci (2003) 1.22
miR-148a plays a pivotal role in the liver by promoting the hepatospecific phenotype and suppressing the invasiveness of transformed cells. Hepatology (2013) 1.22
Therapeutic effects of microRNA-582-5p and -3p on the inhibition of bladder cancer progression. Mol Ther (2013) 1.19